FogPharma announced a $145 million Series E financing round led by Nextech Invest to support ongoing clinical development of FOG-001 and accelerate Helicon peptide portfolio.
Amount Raised
$145 Million
Round Type
Series E
CambridgeBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalBiopharmaInvestors
Description
FogPharma successfully closed a $145 million Series E financing round led by Nextech Invest, with participation from other new investors including RA Capital Management, Rock Springs Capital, General Catalyst, Marshall Wace, Samsara Biocapital, Foresite Capital, Symbiosis, Catalio Capital Management, Sixty Degree Capital, and former chairman and CEO of Johnson & Johnson, Alex Gorsky. The financing will support the ongoing clinical development of FOG-001 and accelerate the development of its robust portfolio of unique discovery programs.
Quick answer
Parabilis Medicines raised $145 Million in a Series E round, dated March 1, 2024. Investors: Milky Way Investments, Invus, Ven Bio Partners, Farallon Capital Management, T. Rowe Price Associates, Cormorant Asset Management, GV and Fidelity Management & Research Company. Parabilis Medicines is based in Cambridge, Massachusetts, United States.
- How much did Parabilis Medicines raise?
- Parabilis Medicines raised $145 Million in a Series E round on March 1, 2024.
- Who invested in Parabilis Medicines?
- Milky Way Investments, Invus, Ven Bio Partners, Farallon Capital Management, T. Rowe Price Associates, Cormorant Asset Management, GV and Fidelity Management & Research Company are named as investors in this round.
- What does Parabilis Medicines do?
- Parabilis Medicines™ is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people living with cancer.
- Where is Parabilis Medicines based and how big is it?
- Parabilis Medicines is based in Cambridge, Massachusetts, United States. Fundz records about 170 employees.
- Who are the decision-makers at Parabilis Medicines?
- Fundz holds 1 contact at Parabilis Medicines, including the Chairman, CEO and President. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Healthcare and Therapeutics around the same time
Companies in the same sectors as Parabilis Medicines that raised within 45 days of this round, from Fundz verified event records.
- Crinetics Pharmaceuticals raised $350M on March 1, 2024.
- vTv Therapeutics Inc. raised $51M on February 27, 2024.
- TORL BioTherapeutics raised $158M (Series B) on April 10, 2024.
- BioLineRx Ltd raised $20M (Pre-Seed) on April 10, 2024.
- TORL BioTherapeutics raised $158M on April 4, 2024.
- AEON Biopharma raised $15M (Convertible Note) on March 21, 2024.
Who to call at Parabilis Medicines, and when
A new round usually means Parabilis Medicines is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Parabilis Medicines raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Parabilis Medicines, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Parabilis Medicines. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Parabilis Medicines raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Parabilis Medicines raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.